| Avidity Biosciences is a biopharmaceutical company developing a new class of RNA therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. Co.'s lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare monogenic muscle disease. Co. pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy, and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy. The RNA average annual return since 2020 is shown above.
The Average Annual Return on the RNA average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RNA average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RNA average annual return calculation with any dividends reinvested as applicable (on ex-dates).